These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 16960863)

  • 21. Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: a pilot study.
    Wong GK; Wong R; Mok V; Wong A; Fan D; Leung G; Chan A; Poon WS
    J Clin Pharm Ther; 2009 Dec; 34(6):657-63. PubMed ID: 20175798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
    Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
    Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Galantamine treatment of vascular dementia: a randomized trial.
    Auchus AP; Brashear HR; Salloway S; Korczyn AD; De Deyn PP; Gassmann-Mayer C;
    Neurology; 2007 Jul; 69(5):448-58. PubMed ID: 17664404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
    Karaman Y; Erdoğan F; Köseoğlu E; Turan T; Ersoy AO
    Dement Geriatr Cogn Disord; 2005; 19(1):51-6. PubMed ID: 15383747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.
    Grossberg GT; Olin JT; Somogyi M; Meng X
    Int J Clin Pract; 2011 Apr; 65(4):465-71. PubMed ID: 21309961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cholinesterase inhibitors for Parkinson's disease dementia.
    Maidment I; Fox C; Boustani M
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004747. PubMed ID: 16437494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
    Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
    Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.
    Burns A; Spiegel R; Quarg P
    Int J Geriatr Psychiatry; 2004 Mar; 19(3):243-9. PubMed ID: 15027039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term rivastigmine treatment in a routine clinical setting.
    Minthon L; Wallin AK; Eriksson S; Wattmo C; Andreasen N
    Acta Neurol Scand; 2009 Mar; 119(3):180-5. PubMed ID: 18759798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
    Rolinski M; Fox C; Maidment I; McShane R
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rivastigmine for Alzheimer's disease.
    Desai AK; Grossberg GT
    Expert Rev Neurother; 2005 Sep; 5(5):563-80. PubMed ID: 16162080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hallucinations predict attentional improvements with rivastigmine in dementia with lewy bodies.
    McKeith IG; Wesnes KA; Perry E; Ferrara R
    Dement Geriatr Cogn Disord; 2004; 18(1):94-100. PubMed ID: 15087584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rivastigmine for subcortical vascular dementia.
    Román GC
    Expert Rev Neurother; 2005 May; 5(3):309-13. PubMed ID: 15938663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
    Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.
    Bullock R; Cameron A
    Curr Med Res Opin; 2002; 18(5):258-64. PubMed ID: 12240787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study.
    Mahlberg R; Walther S; Eichmann U; Tracik F; Kunz D
    Arch Gerontol Geriatr; 2007; 45(1):19-26. PubMed ID: 16963137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences.
    Emre M; Cummings JL; Lane RM
    J Alzheimers Dis; 2007 Jul; 11(4):509-19. PubMed ID: 17656830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
    Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK
    Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias.
    Ballard C; Lane R; Barone P; Ferrara R; Tekin S
    Int J Clin Pract; 2006 Jun; 60(6):639-45. PubMed ID: 16805745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of rivastigmine on cognitive function in patients with traumatic brain injury.
    Silver JM; Koumaras B; Chen M; Mirski D; Potkin SG; Reyes P; Warden D; Harvey PD; Arciniegas D; Katz DI; Gunay I
    Neurology; 2006 Sep; 67(5):748-55. PubMed ID: 16966534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.